Barinthus Biotherapeutics (BRNS) Return on Capital Employed (2021 - 2026)
Barinthus Biotherapeutics (BRNS) reported Return on Capital Employed of 67.38% for Q1 2026, down 1590.0% on a YoY basis from 4.52% in Q1 2025, and up 10.55% quarter-over-quarter from 75.33% in Q4 2025.
Barinthus Biotherapeutics (BRNS) Return on Capital Employed (2021 - 2026) Analysis & Trends
Barinthus Biotherapeutics has reported Return on Capital Employed for 6 years, with the latest figure at 67.38% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 1590.0% year-over-year to 67.38%; the trailing twelve-month figure through Mar 2026 stood at 67.38% (down 1590.0% YoY), and the FY2025 full-year result was 59.18%, down 1960.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 67.38%, up from 75.33% in the prior quarter.
- The five-year high for Return on Capital Employed was 1.67% in Q3 2022, with the low at 75.87% in Q3 2025.
- Historically, Return on Capital Employed has averaged 36.99% across 5 years, with a median of 40.16% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 1684 bps — and 2023, when it sank 4223 bps.
- Barinthus Biotherapeutics' Return on Capital Employed stood at 1.52% in 2022, then sank by 2529 bps to 40.03% in 2023, then fell by 7 bps to 42.79% in 2024, then slumped by 76 bps to 75.33% in 2025, then climbed by 11 bps to 67.38% in 2026.
- The last three Return on Capital Employed figures came in at 67.38% (Q1 2026), 75.33% (Q4 2025), and 75.87% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -107.40% |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -50.43% |
| 10 | Barinthus Biotherapeutics | 27.57 Mn | -39.54 Mn | - | -67.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67.38% |
| Dec 31, 2025 | -75.33% |
| Sep 30, 2025 | -75.87% |
| Jun 30, 2025 | -62.33% |
| Mar 31, 2025 | -51.48% |
| Dec 31, 2024 | -42.79% |
| Sep 30, 2024 | -37.40% |
| Jun 30, 2024 | -40.16% |
| Mar 31, 2024 | -40.87% |
| Dec 31, 2023 | -40.03% |
| Sep 30, 2023 | -40.56% |
| Jun 30, 2023 | -27.16% |
| Mar 31, 2023 | -10.28% |
| Dec 31, 2022 | -1.52% |
| Sep 30, 2022 | 1.67% |
| Jun 30, 2022 | -3.04% |
| Mar 31, 2022 | -14.38% |
| Dec 31, 2021 | -17.56% |
| Sep 30, 2021 | -15.16% |
| Jun 30, 2021 | -16.65% |